Trial Condition(s):
Postmenopause, Hormone Replacement Therapy
Study to evaluate the effect of Angeliq® and ActivelleTM on hemostasis parameters in healthy postmenopausal women
Bayer Identifier:
91203
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
59
Trial Dates
Phase
1
Could I receive a placebo?
No
Products
Angeliq (E2/DRSP, BAY86-4891)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
Status
| Locations | Status |
|---|
Trial Design
A multi-center, open-label, randomized study to evaluate the effect of Angeliq® and ActivelleTM on hemostasis in 60 healthy postmenopausal women over 7 treatment cycles
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
